Patents Assigned to Cypress Pharmaceutical, Inc.
-
Patent number: 10150784Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.Type: GrantFiled: July 18, 2016Date of Patent: December 11, 2018Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert L. Lewis
-
Patent number: 9937134Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.Type: GrantFiled: July 20, 2015Date of Patent: April 10, 2018Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert Lewis
-
Patent number: 9889157Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: GrantFiled: April 3, 2017Date of Patent: February 13, 2018Assignee: Cypress Pharmaceuticals, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Patent number: 9610267Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: GrantFiled: May 16, 2016Date of Patent: April 4, 2017Assignee: Cypress Pharmaceuticals, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Patent number: 9394318Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.Type: GrantFiled: November 26, 2013Date of Patent: July 19, 2016Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert L. Lewis
-
Patent number: 9339481Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: GrantFiled: April 3, 2013Date of Patent: May 17, 2016Assignee: Cypress Pharmaceuticals, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20140186408Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.Type: ApplicationFiled: November 26, 2013Publication date: July 3, 2014Applicant: Cypress Pharmaceutical, Inc.Inventor: Robert L. Lewis
-
Publication number: 20140057859Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.Type: ApplicationFiled: June 12, 2013Publication date: February 27, 2014Applicant: Cypress Pharmaceuticals, Inc.Inventor: Robert Lewis
-
Publication number: 20140010877Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: ApplicationFiled: April 3, 2013Publication date: January 9, 2014Applicant: Cypress Pharmaceuticals, Inc.Inventor: Cypress Pharmaceuticals, Inc.
-
Patent number: 8466128Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for malting and using the same.Type: GrantFiled: January 29, 2008Date of Patent: June 18, 2013Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert Lewis
-
Publication number: 20120282352Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: ApplicationFiled: July 9, 2012Publication date: November 8, 2012Applicant: CYPRESS PHARMACEUTICAL, INC.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20120277183Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Applicant: CYPRESS PHARMACEUTICAL, INC.Inventors: Robert L. Lewis, Charles E. Day
-
Patent number: 8247000Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: GrantFiled: April 10, 2009Date of Patent: August 21, 2012Assignee: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Patent number: 8236358Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.Type: GrantFiled: April 12, 2012Date of Patent: August 7, 2012Assignee: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20120195964Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.Type: ApplicationFiled: April 12, 2012Publication date: August 2, 2012Applicant: CYPRESS PHARMACEUTICAL, INC.Inventors: Robert L. Lewis, Charles E. Day
-
Patent number: 7943597Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.Type: GrantFiled: April 8, 2008Date of Patent: May 17, 2011Assignee: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20110045063Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: ApplicationFiled: April 10, 2009Publication date: February 24, 2011Applicant: Cypress Pharmaceutical, Inc.Inventors: Robert Lewis, Charles Day
-
Publication number: 20090269399Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.Type: ApplicationFiled: April 10, 2009Publication date: October 29, 2009Applicant: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20090253652Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.Type: ApplicationFiled: May 6, 2009Publication date: October 8, 2009Applicant: Cypress Pharmaceutical, Inc.Inventors: Robert L. Lewis, Charles E. Day
-
Publication number: 20080193521Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.Type: ApplicationFiled: April 8, 2008Publication date: August 14, 2008Applicant: CYPRESS PHARMACEUTICAL, INC.Inventors: Robert L. Lewis, Charles E. Day